Co-Diagnostics, Inc. (0A50)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 0.559 |
|---|---|
| 52-week range | 0.547 – 46.173 |
| Return, 1 month / 3 months | −48.7% / −74.3% |
| Return, 1 year / 3 years | −94.2% / −98.3% |
| Trend | Below its 200-day average |
| RSI (14) | 25 |
| Volatility (1 year) | 213.1% |
| Worst drawdown (1 year) | -96.8% |
| Average daily value traded | 0.01M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Co-Diagnostics is a molecular diagnostics company that designs and sells tests and reagents used to detect genetic material in samples. Its products centre on real-time polymerase chain reaction technology, sold under the Logix Smart brand, and are used by clinical laboratories and healthcare providers. The company also supplies the reagents and instruments needed to run those tests. It is based in Salt Lake City, Utah, in the United States, and serves customers in several countries.
Co-Diagnostics, Inc. trades under the code 0A50 on the London Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Co-Diagnostics, Inc. (0A50) trades on the London Exchange in UK. It last closed at USD 0.559 on 23 October 2026.
Its price-based Market X-Ray is 3 out of 100 (a weak price profile), ranking 3,784 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 94.2% and over the last three months it fell 74.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 1 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -75.8% | ||
| From 52-week high | -98.4% | ||
| Momentum | 1 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -74.3% | ||
| 6-month return | -67.3% | ||
| 12-month return, skipping the last month | -88.7% | ||
| Stability (higher is calmer) | 1 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 213.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -96.8% | ||
| Liquidity | 12 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −13.4% |
|---|---|
| 1 month | −48.7% |
| 3 months | −74.3% |
| 6 months | −67.3% |
| 1 year | −94.2% |
| 3 years | −98.3% |
| 5 years | −99.8% |
Signals
| 50-day / 200-day average | 1.076 / 2.308 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.103 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.